VPA is one of the leading antiepileptic drugs (AEDs). However its clinical use is restricted in women of child-bearing age and in children due to its teratogenicity and hepatotoxicity. Therefore, there is a substantial need to develop non-teratogenic and non-hepatotxic CNS-active VPA derivatives. The design and development of PID enantiomers can provide a suitable answer to this clinical need.
This grant from the Epilepsy Therapy Project was matched with an equal grant from Jazz Pharmaceuticals, Inc. (www.jazzpharmaceuticals.com), Palo Alto, California.